Search Results

You are looking at 311 - 320 of 2,911 items for :

  • Refine by Access: All x
Clear All
Full access

Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study

Mary Katherine Montes de Oca, Lauren E. Wilson, Rebecca A. Previs, Anjali Gupta, Ashwini Joshi, Bin Huang, Maria Pisu, Margaret Liang, Kevin C. Ward, Maria J. Schymura, Andrew Berchuck, and Tomi F. Akinyemiju

improved survival outcomes, and lack of concordance with the NCCN Guidelines is an independent predictor of worse survival. 6 , 10 , 11 Some evidence suggests that equal care leads to similar outcomes among Black and White women with advanced OC 12 , 13

Full access

Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors

Presented by: Brian T. Hill

In recent years, the treatment landscape for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has seen significant advancements, ushering in an era of targeted therapies that have transformed patient outcomes

Full access

Interdigitating Dendritic Cell Sarcoma

Venkata K. Pokuri, Mihai Merzianu, Shipra Gandhi, Junaid Baqai, Thom R. Loree, and Seema Bhat

outcomes of documented IDCS cases Discuss challenges in the accurate pathologic diagnosis, staging, and treatment of patients with IDCS Case Report An 81-year-old Caucasian man presented with a 4-month history of a gradually enlarging

Full access

Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price

Daniel Tobias Michaeli and Thomas Michaeli

-analyses was conducted for clinical trials with available outcome data. HRs for OS and PFS were meta-analyzed in all RCTs, as were RRs for tumor response. ORRs were meta-analyzed in all single-arm trials. Differences between HRs, RRs, and ORRs for breakthrough

Full access

Measuring Quality in Oncology: Challenges and Opportunities

Jessica K. DeMartino

Executive Summary Variations in the quality of cancer care are well documented. 1 , 2 A key element of quality monitoring is standardized measures of care. Quality measures may include both process and outcome measures. Process measurement is

Full access

QIM19-134: Improving Access to Bone Marrow Transplant in the Community: The Memorial Sloan Kettering Cancer Alliance Shared Care Program

Craig Sauter, W. Jeffrey Baker, Elizabeth Rodriguez, Silvia Willumsen, Barbara Morcerf, Kristi Gafford, Jessica Kennington, Richard Korman, Peter Yu, David Pfister, and Sergio Giralt

patients with hematologic malignancies and the timing of a referral for transplant has significant impact on patient outcomes (National Marrow Donor Program, available at: https://bethematchclinical.org/transplant-indications-and-outcomes/additional-outcomes/timing-impact-on-outcomes

Full access

Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers

Alison R. Walker and Guido Marcucci

is used to determine outcome risk and direct treatment strategies for patients, including allogeneic stem cell transplantation (SCT) in first complete remission. However, in 40% to 50% of patients, chromosome aberrations are not detected, making it

Full access

Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

data, 14 , 15 whereas cyclophosphamide escalation did not lead to improved outcomes. 16 , 17 These results are informative but require updating as CMF, CAF, and FEC are inferior to third-generation chemotherapy regimens currently used in the adjuvant

Full access

The Integration of Chemotherapy and Surgery for Bladder Cancer

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

cancer outcomes after radical cystectomy . Urology 2003 ; 61 : 105 – 108 . 6 Konety BR Joslyn SA O'Donnell MA . Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the

Full access

HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience

Sonali Agrawal, Caitlin R. Meeker, Sandeep Aggarwal, Elizabeth A. Handorf, Sunil Adige, Efrat Dotan, Crystal S. Denlinger, William H. Ward, Jeffrey M. Farma, and Namrata Vijayvergia